Long term outcome of patients with progressive multiple myeloma treated with intermediate dose thalidomide and high dose dexamethasone: a single center experience

Mihou, D; Hatjicharissi, E; Georgiou, E; Banti, A; Verrou, E; Papaioannou, M; Christakis, J; Kaloutsi, V; Zervas, K

dc.contributor.author	Mihou, D	en
dc.contributor.author	Hatjicharissi, E	en
dc.contributor.author	Georgiou, E	en
dc.contributor.author	Banti, A	en
dc.contributor.author	Verrou, E	en
dc.contributor.author	Papaioannou, M	en
dc.contributor.author	Christakis, J	en
dc.contributor.author	Kaloutsi, V	en
dc.contributor.author	Zervas, K	en
dc.date.accessioned	2014-03-01T01:54:15Z
dc.date.available	2014-03-01T01:54:15Z
dc.date.issued	2005	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/27277
dc.relation.uri	http://www.eae.gr/haema/pdf/84-09.pdf	en
dc.subject	Adverse Effect	en
dc.subject	Dexamethasone	en
dc.subject	Long-term Outcome	en
dc.subject	Multiple Myeloma	en
dc.subject	Overall Survival	en
dc.subject	Peripheral Neuropathy	en
dc.subject	Response Rate	en
dc.subject	Salvage Therapy	en
dc.subject	Complete Response	en
dc.subject	Event Free Survival	en
dc.subject	High Dose	en
dc.subject	Non Responders	en
dc.subject	Overall Response Rate	en
dc.subject	Progressive Disease	en
dc.subject	Partial Response	en
dc.title	Long term outcome of patients with progressive multiple myeloma treated with intermediate dose thalidomide and high dose dexamethasone: a single center experience	en
heal.type	journalArticle	en
heal.publicationDate	2005	en
heal.abstract	The combination of thalidomide and dexamethasone has yielded an about 50% response rate as salvage therapy in multiple myeloma patients. The aim of the present study was to evaluate, after a median follow up of 22 months, the long term outcome of 50 patients with progressive myelo- ma, who were treated with the combination of intermediate dose thalidomide (200-400 mg/d)	en